Hypogonadism in human immunodeficiency virus-positive men

Korean Journal of Urology

Volumn 55, Issue 1, 2014, Pages 9-16

  Ashby, Jane ^a   Goldmeier, David ^b   Sadeghi Nejad, Hossein ^c  

^a BERKSHIRE HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Androgens; HIV; Hypogonadism; Testosterone

Indexed keywords

ANTIRETROVIRUS AGENT; ESTRADIOL; FLUOXETINE; FOLLITROPIN; INTERLEUKIN 1BETA; LUTEINIZING HORMONE; NANDROLONE DECANOATE; OXYMETHOLONE; PLACEBO; RECREATIONAL DRUG; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TUMOR NECROSIS FACTOR ALPHA;

AGE; ANDROGEN DEFICIENCY; BONE DENSITY; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG ABUSE; ERECTILE DYSFUNCTION; GEL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; LIVER TOXICITY; MALE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MIXED INFECTION; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTOSTERONE METABOLISM; VIRUS LOAD; VIRUS REPLICATION; WASTING SYNDROME;

EID: 84892881437     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2014.55.1.9     Document Type: Review

References (64)

1. UNAIDS. AIDS epidemic update [Internet]. Geneva: UNAIDS; c2009 [cited 2012 Jan 14]. http://www.unaids.org/en/media/unaids/ contentassets/dataimport/pub/report/2009/jc1700_epi_update_ 2009_en.pdf.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853-60.
3. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280: 1497-503.
4. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84(3 Pt 2):611-6.
5. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991;5:729-33.
6. Laudat A, Blum L, Guechot J, Picard O, Cabane J, Imbert JC, et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 1995;133:418-24.
7. Moreno-Perez O, Escoin C, Serna-Candel C, Portilla J, Boix V, Alfayate R, et al. The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected males. J Sex Med 2010;7:2873-83.
8. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
9. Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 2007;21:9-19.
10. Wunder DM, Bersinger NA, Fux CA, Mueller NJ, Hirschel B, Cavassini M, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007;12:261-5.
11. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004;39:1223-30.
12. Dube MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007;45:120-6.
13. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6.
14. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
15. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
16. Siddiqui J, Phillips AL, Freedland ES, Sklar AR, Darkow T, Harley CR. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr Med Res Opin 2009;25:1307-17.
17. Desyatnik M, Baaj A, Fisher A. The prevalence of hypogonadism in HIV-infected patients receiving HAART (TuPeB3180). Poster session presented at: 13th International AIDS Conference; 2000 Jul 9-14; Durban, South Africa.
18. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240-4.
19. Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab 2002;283:E138-45.
20. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234-8.
21. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568-72.
22. Cubero JM, Domingo P, Sambeat M, Ordonez-Llanos J, Rodriguez-Espinosa J, Snchez-Quesada JL, et al. Prevalence of metabolic syndrome among human immunodeficiency virus-infected subjects is widely influenced by the diagnostic criteria. Metab Syndr Relat Disord 2011;9:345-51.
23. Fernández-Berges D, Cabrera de Leon A, Sanz H, Elosua R, Guembe MJ, Alzamora M, et al. Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal. DARIOS study. Rev Esp Cardiol (Engl Ed) 2012;65:241-8.
24. Jordan HT, Tabaei BP, Nash D, Angell SY, Chamany S, Kerker B. Metabolic syndrome among adults in New York City, 2004 New York City Health and Nutrition Examination Survey. Prev Chronic Dis 2012;9:E04.
25. Lao XQ, Zhang YH, Wong MC, Xu YJ, Xu HF, Nie SP, et al. The prevalence of metabolic syndrome and cardiovascular risk factors in adults in southern China. BMC Public Health 2012;12:64.
26. Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS 2011;22:43-5.
27. Richardson D, Goldmeier D, Frize G, Lamba H, De Souza C, Kocsis A, et al. Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med 2007;4:502-8.
28. Guaraldi G, Beggi M, Zona S, Luzi K, Orlando G, Carli F, et al. Erectile dysfunction is not a mirror of endothelial dysfunction in HIV-infected patients. J Sex Med 2012;9:1114-21.
29. Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 2002;30: 187-90.
30. McLachlan RI, Allan CA. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts? J Clin Endocrinol Metab 2004;89:5916-9.
31. Health Protection Agency. HIV in the United Kingdom: 2010 Report. Health Prot Rep 2010:4(47).
32. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc 2009;57: 2129-38.
33. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005;41:1794-803.
34. Cejtin HE, Kalinowski A, Bacchetti P, Taylor RN, Watts DH, Kim S, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006;108: 1423-31.
35. Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005;41:1517-24.
36. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis 2001;184:1325-7.
37. Fantry LE, Zhan M, Taylor GH, Sill AM, Flaws JA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 2005;19:703-11.
38. Cohan GR. HIV-associated hypogonadism. AIDS Read 2006;16: 341-5, 348, 352-4.
39. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 2011;25:501-15.
40. Ebeling PR. Androgens and osteoporosis. Curr Opin Endocrinol Diabetes Obes 2010;17:284-92.
41. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003;37 Suppl 2:S132-6.
42. Wisniewski AB, Brown TT, John M, Frankowicz JK, Cofranceso J Jr, Golub ET, et al. Hypothalamic-pituitary-gonadal function in men and women using heroin and cocaine, stratified by HIV status. Gend Med 2007;4:35-44.
43. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002;2:692-9.
44. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000;283:763-70.
45. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000;133:348-55.
46. Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;129:18-26.
47. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000;57:141-7.
48. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol 1999;19:19-27.
49. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-54.
50. Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 2010;11:2095-106.
51. Dobs AS, Cofrancesco J, Nolten WE, Danoff A, Anderson R, Hamilton CD, et al. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 1999;107: 126-32.
52. Scott JD, Wolfe PR, Anderson P, Cohan GR, Scarsella A. Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. HIV Clin Trials 2007;8:412-20.
53. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007;92:1049-57.
54. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335-9.
55. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Med 2006;7:299-310.
56. Hengge UR, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 2003;17:699-710.
57. Gold J, High HA, Li Y, Michelmore H, Bodsworth NJ, Finlayson R, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996;10:745-52.
58. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996;10: 1657-62.
59. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997;11:1347-52.
60. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000;85:60-5.
61. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004;24:379-85.
62. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
63. Clay PG, Lam AI. Testosterone replacement therapy for bone loss prevention in HIV-infected males. Ann Pharmacother 2003;37: 582-5.
64. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001;86: 2020-6.